Federal dollars from Cancer Moonshot is expected to help companies develop innovative cancer treatments and diagnostics in St. Louis.

General Cancer Research

Arch Oncology in St. Louis is engaged in a cellular battle with a unique approach for killing cancer. The immunotherapy developed and studied in Arch Oncology’s lab is based on what’s called a “don’t eat me signal”, which is key to a cell’s survival.

St. Louis-based Immunophotonics, a clinical-stage biotechnology company, is advancing interventional immuno-oncology with a novel technology designed to treat many kinds of cancer.

Cancer Type: Brain Tumor

A St. Louis clinical-stage biotechnology company is supercharging particular immune cells and training those cells to become the natural killers they’re meant to be. That’s the idea behind new ammunition developed by Wugen, Inc., to combat a range of blood and solid tumor cancers. Wugen is developing a cellular therapy using natural killer (NK) cells, one of the body’s natural defenses against cancer.  

Milan Chheda, MD, neuro-oncologist and associate professor of medicine at Washington University School of Medicine in St. Louis, wants to be able to provide hope to his patients suffering from glioblastoma, the most aggressive and deadly brain tumor.

Zika virus may be a key to unlocking the power of immunotherapy for glioblastoma, the most aggressive and deadly brain tumor.

Brain Tumor Center at Siteman Cancer Center is combining efforts in the lab with efforts in the clinic to provide transformative research and patient care on the Washington University Medical Campus in St. Louis.

Cancer Type: Breast Cancer

Trial:  201407100 
Disease Site:  Breast
A Phase 1B Clinical Trial to evaluate the safety and immune response to a Mammaglobin-A DNA Vaccine in ER+, HER2-Breast Cancer Patients undergoing Neoadjuvant Endocrine Therapy or Chemo Therapy
Principle Investigator:  William Gillanders, MD – Surgical Oncologist, Siteman Cancer Center / Professor/ Vice Chair for Research/Department of Surgery, Washington University School of Medicine in St. Louis
Sponsor:  Washington University School of Medicine
Collaborators:
Rising Tide Foundation
United States Department of Defense
Ages Available for Study: 18 Years and older (Adult/Older Adult/Female) Does not accept healthy volunteers
For Trial Info:  Phone: (800) 600-3606  / Email: info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  201611010
Disease Site:  Breast
Endocrine Treatment Alone as Primary Treatment for Elderly Patients with Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
Principle Investigator:  Rebecca Aft, MD, PhD – Surgeon, Siteman Cancer Center/Washington University School of Medicine in St. Louis Professor of Surgery, General Surgery, Endocrine & Oncologic Surgery 
Collaborator:  Genomic Health®, Inc
Ages Available for Study: 70 years and older (Adult/Older Adult/Female) Does not accept healthy volunteers
For Trial Info:  Phone: (800) 600-3606 / Email:info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  201902119
Disease Site:  Breast
Randomized phase 2 clinical trial of nab-paclitaxel + MEDI4736 (durvalumab) + neoantigen vaccine vs. nab-paclitaxel + MEDI4736 (durvalumab) in patients with Metastatic Triple Negative Breast Cancer
Principle Investigator:  William Gillanders, MD Surgical Oncologist, Siteman Cancer Center / Professor / 
Vice Chair for Research/Department of Surgery, Washington University School of Medicine in St. Louis
Sponsor:  National Cancer institute (NCI)
Ages Available for Study: 18 Years and older (Adult/Older Adult/All Sexes) Does not accept healthy volunteers
For Trial Info:  Phone: (800) 600-3606  / Email: info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  201911082
Disease Site:  Breast
A randomized Phase I/II trial of Fulvestrant and Abemaciclib in combination with Copanlisib (FAC) versus fulvestrant and abemaciclib alone (FA) for endocrine-resistant, hormone receptor positive, HER2 negative Metastatic Breast Cancer (FAC vs FA)
Principle Investigator:  Cynthia Ma, MD, PhD – Medical Oncologist, Siteman Cancer Center / Professor of Medicine, Division of Oncology, Section of Breast Oncology, Washington University School of Medicine in St. Louis
Sponsor:  National Cancer institute (NCI)
Ages Available for Study: 18 years and older (Adult/Older Adult/All Sexes) Does not accept healthy volunteers
For Trial Info:  Phone: (800) 600-3606  / Email: info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  202007016
Disease Site:  Breast
Phase I/II study to evaluate safety and tolerability of Cabiralizumab in combination with Nivolumab and Neoadjuvant Chemotherapy in patients with localized triple-negative Breast Cancer
Principle Investigator:  Andrew A. Davis, MD – Medical Oncologist/Brest Cancer Specialist, Siteman Cancer Center / Assistant Professor of Medicine, Division of Oncology – Washington University School of Medicine in St. Louis
Sponsor:  Washington University of Medicine
Collaborator:  Bristol-Meyers Squibb
Ages Available for Study: 18 years and older (Adult/Older Adult/All Sexes) Does not accept healthy volunteers
For Trial Info: (800) 600-3606 / Email:  info@ccadmin.wustl.edu
Learn more about this study at: clinicaltrials.gov

Trial:  202104085
Disease Site:  Breast
Evaluation of Single Fraction Accelerated Partial Breast Irradiation vs. Five Fraction Accelerated Partial Breast Irradiation for Low-risk Stage 0 and I Breast Carcinoma – BreaStBRT
Principle Investigator:  Imran Zoberi, MD – Medical Director of Radiation Oncology, Siteman Cancer Center at Barnes-Jewish West County Hospital /Professor of Radiation Oncology at Washington University School of Medicine in St. Louis
Sponsor:  Washington University of Medicine
Collaborator:  The Foundation for Barnes-Jewish Hospital
Ages Available for Study:  50 Years and older (Adult/Older Adult/Female) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email:  info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  201902108
Disease Site:  Breast
A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) in Combination with Paclitaxel and Multiple Novel Oncology Therapies and Durvalumab (MEDI4736) + Paclitaxel for First-line Metastatic Triple Negative Breast Cancer
Principle Investigator:  Cynthia Ma, MD, PhD – Medical Oncologist, Siteman Cancer Center / Professor of Medicine, Division of Oncology, Section of Breast Oncology, Washington University School of Medicine in St. Louis
Sponsor:  AstraZeneca
Ages Available for Study: 18 to 130 years (Adult, Older Adult, Female) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  202003106
Disease Site:  Breast
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-Surgery Chemo and Targeted TherapyEA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response Part 1 Component of: The CompassHER2 Trials (COMprehensive use of Pathologic response Assessment to optimize therapy in HER2-positive breast cancer)
Principle Investigator:  Nusayba Bagegni, MD – Medical Oncologist, Siteman Cancer Center / Assistant Professor of Medicine, Division of Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor: Eastern Cooperative Oncology Group (ECOG-ACRIN Cancer Research Group)
Collaborator:  National Cancer Institute (NCI)
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email:  info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  202104085
Disease Site:  Breast
Evaluation of Single Fraction Accelerated Partial Breast Irradiation vs. Five Fraction Accelerated Partial Breast Irradiation for Low-risk Stage 0 and I Breast Carcinoma – BreaStBRT
Principle Investigator:  Imran Zoberi, MD – Medical Director of Radiation Oncology, Siteman Cancer Center at Barnes-Jewish West County Hospital /Professor of Radiation Oncology at Washington University School of Medicine in St. Louis
Sponsor:  Washington University of Medicine
Collaborator:  The Foundation for Barnes-Jewish Hospital
Ages Available for Study: 50 years & older (Adult/Older Adult/Female) Does Not accept healthy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  201701042
Disease Site:  Breast
Testing Olaparib Either Alone or in Combination with Atezumab in BRCA Mutant Non-HER2-positive Breast Cancer – A Phase II Open-Label, Randomized Study of PARP inhibition (olaparib) Either Alone or in Combination with Anti-PD-LI Therapy (atezolizumab;MPDL3280A) in Homologous DNA Repair (HDR) Deficient Triple NegativeBreast Cancer (TNBC)
Principle Investigator:  Haeseong Park, MD, MPH – Oncologist/Center for Advanced Medicine, Siteman Cancer Center Assistant Professor, Medicine Division of Oncology/Washington University School of Medicine in St. Louis
Sponsor:  National Cancer institute (NCI)
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  201902108
Disease Site:  Breast
A Study of Novel Anti-cancer Agents in Patients with Metastatic Triple Negative Breast Cancer (BEGONIA)
A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) in Combination with Paclitaxel and Multiple Novel Oncology Therapies and Durvalumab (MEDI4736) + Paclitaxel for First-line Metastatic Triple Negative Breast Cancer
Principle Investigator:  Cynthia Ma, MD, PhD – Medical Oncologist, Siteman Cancer Center / Professor of Medicine, Division of Oncology, Section of Breast Oncology, Washington University School of Medicine in St. Louis
Sponsor:  AstraZeneca
Ages Available for Study: 18 to 130 years (Adult/Older Adult/Female) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  202001160
Disease Sites:  Anus; Bones and Joints; Brain and Nervous System; Breast; Cervix; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Ill-Defined Sites; Kidney; Larynx; Liver; Lung; Melanoma, Skin; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Unknown Sites; Urinary Bladder
Study of AMG in Adult Participants with Advanced Solid Tumors 
A Phase 1 (Cancer Control), Multicenter, Open-label, Dose-Exploration and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 650 in Subjects with Advanced Solid Tumors
Principle Investigator:  Ramaswamy Govindan – Medical Oncologist, Siteman Cancer Center/Professor of Medicine, Division of Oncology, Washington University School of Medicine in St. Louis
Sponsor:  Amgen
Ages Available for Study: 18 to 99 Years (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  202003106
Disease Site:  Breast
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy. EA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response. 
Part 1 Component of: The CompassHER2 Trials (COMprehensive use of Pathologic response Assessment to optimize therapy in HER2-positive breast cancer)
Principle Investigator:  Nusayba Bagegni, MD – Medical Oncologist, Siteman Cancer Center / Assistant Professor of Medicine, Division of Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor:  Eastern Cooperative Oncology Group (ECOG-ACRIN Cancer Research Group)
Collaborator: National Cancer Institute (NCI)
Ages Available for Study: 18 Years & Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  202004058
Disease Site:  Breast
A study to assess overall response rate by inducing an inflammatory phenotype in Metastatic Breast Cancer with the Oncolytic Reovirus Peareorep in Combination with anti-PD-L1 Avelumab and Paclitaxel BRACELET-1 Study. Phase II
Principle Investigator:  Katherine Clifton, MD – Siteman Cancer Center Medical Oncologist / Assistant Professor of Medicine, Division of Oncolgy/Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor:  Oncolytics Biotech
Collaborator: PRECOG, LLC
Ages Available for Study: 18 Years and Older (Adult/Older Adult/Female) Does Not accept healthy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  202005122 – Patients with Malignant Solid Tumors
Disease Sites:  Anus; Bones and Joints; Breast; Cervix; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Ill-Defined Sites; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, Skin; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Unknown Sites; Urinary Bladder
First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of GEN1046 in subjects with malignant solid tumors. Phase 1/11
Principle Investigator:  Jeffrey Ward, MD, PhD – Medical Oncologist, Siteman Cancer Center / Assistant Professor of Medicine/Division of Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor:  Genmab
Collaborator: BioNTech SE
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  202006122 – Patients with Metastatic Triple Negative Breast Cancer
Disease Site:  Breast
A Study of Pembrolizuab with Carboplatin and Gemcitabine in Patients with Metastatic Triple Negative Breast Cancer
BR-076: A Randomized Phase II clinical trial assessing the Efficacy and Safety of MK-3475 (pembrolizumab) in combination with carboplatin and gemcitabine in patients with metastatic triple negative breast cancer Phase II (Cancer Control)
Principle Investigator:  Foluso Ademuyiwa, MD, MPH, MSCI – Medical Oncologist, Siteman Cancer Center/ Associate Professor of Medicine, Division of Oncology, Section of Breast Oncology, Washington University School of Medicine in St. Louis
Sponsor: Fox Chase Cancer Center
Collaborator: University of Wisconsin, Madison
Ages Available for Study: 8 Years and Older (Adult/Older Adult/Female) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  202007074
Disease Site:  Breast
A Phase 1/2, open-label, dose escalation, and cohort expansion clinical trial to evaluate the safety, tolerability, and pharmacokinetics of ARV-471 in patients with ER+/HER2- locally advanced or metastatic breast cancer (MBC), who have received prior hormonal therapy and chemotherapy in the locally advanced/metastatic setting
Principle Investigator:  Cynthia Ma, MD, PhD – Medical Oncologist, Siteman Cancer Center / Professor of Medicine, Division of Oncology, Section of Breast Oncology, Washington University School of Medicine in St. Louis
Sponsor: Arvinas Estrogen Receptor, Inc.
Collaborator:  Pfizer
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  202007216
Disease Sites:  Breast; Ovary
A Study of LY3484356 in Participants with Advanced or Metastatic Breast Cancer or Endometrial Cancer. EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination with Anticancer Therapies for Patients with ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
Principle Investigator:  Cynthia Ma, MD, PhD – Medical Oncologist, Siteman Cancer Center / Professor of Medicine, Division of Oncology, Section of Breast Oncology, Washington University School of Medicine in St. Louis
Sponsor: Eli Lilly and Company
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial:  202009029
Disease Site:  Breast
A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator’s Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer (DB-06) Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)
Principle Investigator:  Nusayba Bagegni, MD – Medical Oncologist, Siteman Cancer Center / Assistant Professor of Medicine, Division of Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor: AstraZeneca
Collaborator:  Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-Ku, Tokyo
Ages Available for Study:  18 -105 Years (Adult/Older Adult, All Sexes) Does not accept healthy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  202101066
Disease Site:  Breast
A Phase 1 study of LY3484356 in Women With Breast Cancer before having Surgery (EMBER-2): An Open-Label, Preoperative Window Study evaluating the Biological Effects of LY3484356 in Post-menopausal Women with Stage I-III Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Principle Investigator:  Rebecca Aft, MD, PhD – Surgeon, Siteman Cancer Center/Washington University School of Medicine in St. Louis Professor of Surgery, General Surgery, Endocrine & Oncologic Surgery  
Sponsors and Collaborators: Eli Lilly and Company
Ages Available for Study: 18 Years and Older (Adult/Older Adult/Female) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  202102117
Disease Site:  Breast
A Double-Blinded, Phase II Randomized Trial of T-DM1 and Tucatinib Compared with T-DMI Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the compass HER2 Residual Disease (RD) Trial.(Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) 
Principle Investigator:  Nusayba Bagegni, MD – Medical Oncologist, Siteman Cancer Center / Assistant Professor of Medicine, Division of Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor: Alliance for Clinical Trials in Oncology
Collaborators: National Cancer Institute (NCI), Sagen Inc.
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  202103081
Disease Site:  Malanoma, Skin
Phase 2 Study of FLX475 in Combination with Ipilimumab in Advanced Melanoma
Principle Investigator:  Tanner Johanns, MD, PhD – Medical Oncology/Cancer/Immunotherapy,Primary Brain Tumors, Brain Metastases, Melanoma, Merkel Cell Carcinoma,  Siteman Cancer Center / Washington University School of Medicine in St. Louis / Barnes-Jewish Hospital
Sponsor: RAPT Therapeutics, Inc.
Ages Available for Study: 18 Years and older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  202104080
Disease Site:  Breast; Esophagus; Stomach
A Phase 1 open-label, first-in-human, multi-center study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of thorium-227 labeled antibody-chelator conjugate BAY 2701439, in participants with advanced HER2-expressing tumors
Principle Investigator:  Richard Wahl, MD – Nuclear Medicine, Elizabeth E. Malinckrodt Professor of Radiology / Chair, Department of Radiology / Professor of Radiation Oncology
Washington University School of Medicine in St. Louis 
Sponsor: Bayer
Ages Available for Study: 18 Years and older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
clinical-trials-contact@bayer.com
Learn more about this study and qualifying criteria at clinicaltrials.gov

Trial:  202105154
Disease Site: Breast
A Global, Phase 2 (Cancer Control) Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients (ACE-Breast-03) Whose Disease is Resistant or Refractory to T-DM1, and/or T-DXd, and/or Tucatinib-containing Regimens
Principle Investigator:  Nusayba Bagegni, MD – Medical Oncologist, Siteman Cancer Center / Assistant Professor of Medicine, Division of Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor: Ambrx, Inc.
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial:  202108130
Disease Site: Breast
A Phase III (Cancer Control), Double-blind, Randomised Study to Assess Switching to AZD9833 (a Next Generation, Oral SERD) + CDK4/6 Inhibitors (Palbociclib or Abemaciclib) vs Continuing NSAI + CDK4/6 Inhibitorsin HR+/HER2- MBC Patients with Detectable ESR1 Mutation Without Clinical or Radiological Progression During 1L Treatment with NSAI +CDK4/6 Inhibitor 
Principle Investigator:  Cynthia Ma, MD, PhD – Medical Oncologist, Siteman Cancer Center / Professor of Medicine, Division of Oncology, Section of Breast Oncology, Washington University School of Medicine in St. Louis
Sponsor: AstraZeneca
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Ages Available for Study: 18 -130 years (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  202111094
Disease Site: Breast
A Phase 3, Single Arm, Open Label Study of Evaluating Ovarian Suppression Following Three Month Leuprolide Acetate for Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone Receptor Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2-) Negative Breast Cancer
Principle Investigator:  Lindsay Peterson, MD, MSCR – Medical Oncologist, Siteman Cancer Center/ Associate Professor, Division of Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor: Tolmar, Inc.
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Ages Available for Study: 18 – 49 Years (Adult/All Sexes) Does Not accept heathy volunteers
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  2021112042
Disease Site: Breast
EPIK-B4: A phase II (Cancer Control), multi center, randomized, open-label, active controlled study Study of Safety and Efficacy of Dapagliflozin + Metformin XR Versus Metformin XR in Participants with HR+, HER2-, Advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy while on Treatment with Alpelisib and Fulvestrant (EPIK-B4)
Principle Investigator:  Lindsay Peterson, MD, MSCR – Medical Oncologist, Siteman Cancer Center/ Associate Professor, Division of Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor: Novartis Pharmaceuticals
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  202201030
Disease Site: Breast; Colon; Esophagus; Lung; Pancreas; Rectum; Stomach
A Phase I/II (Cancer Control), First-in-Human, Open-Label, Dose-Escalation and Expansion Study of  IMGC936-0901 (Anti-ADAM9 Antibody Drug Conjugate) in Patients with Advanced Solid Tumors
Principle Investigator:  Haeseong Park, MD, MPH – Oncologist/Center for Advanced Medicine, Siteman Cancer Center Assistant Professor, Medicine Division of Oncology/Washington University School of Medicine in St. Louis
Collaborator: MacroGenics
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  202107015
Disease Site: Breast
TK IMPACT: Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) with or without the Addition of DiviTum(R) Serum Thymidine Kinase 1 (TK1) Activity Testing: Physician Decision Impact Study
Principle Investigator:  Nusayba Bagegni, MD – Medical Oncologist, Siteman Cancer Center / Assistant Professor of Medicine, Division of Medical Oncology, Washington University School of Medicine
Sponsor: Washington University School of Medicine in St. Louis
Collaborator: Bivoica
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  201704073
Disease Site: Breast
[18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients with Newly Diagnosed Metastatic Breast Cancer (EAI142) Phase II
Principle Investigator:  Farrokh Dehdasti, MD – Radiologist, Siteman Cancer Center / Professor of Radiology/Senior Vice Chair/Chief, Division of Nuclear Medicine – Washington University School of Medicine in St. Louis
Sponsor: National Cancer Institute (NCI)
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Ages Available for Study: 18 Years and older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  201812035
Disease Site: Breast
RNA Disruption Assay (RDA) – Breast cancer Response Evaluation for Individualized Therapy (BREVITY)
Principle Investigator:  Foluso Bisi Ademuyiwa, MD, MPH, MSCI – Medical Oncologist/Associate Professor of Medicine, Division of Breast Oncology – Siteman Cancer Center / Washington University School of Medicine in St. Louis
Sponsor: Rna Diagnostics Inc.
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Ages Available for Study: 18 Years and Older (Adult/Older Adult/Female) Does Not accept heathy volunteers
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  201905026
Disease Site: Breast; Hodgkin Lymphoma; Non-Hodgkin Lymphoma
Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY)
Principle Investigator:  Simon Haroutounian, PhD/MSc – Anesthesiology / Chief of the Division of Clinical and Translational Research (DoCTR); Chief of Clinical Pain Research – Washington University Pain Center/Washington University School of Medicine in St. Louis
Sponsor: Disarm Therapeutics
Collaborator: Eli Lilly and Company
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Ages Available for Study: 18 Years and Older (Adult/Older Adult) Does Not accept heathy volunteers
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial:  201905083
Disease Site: Breast 
MammaPrint, BluePrint, and Full-genome Data Linked with Data to Evaluate New Gene Expression Profiles: (FLEX Registry)
The FLEX Registry will be implemented to operate as a large-scale, population based, prospective registry. All patients with stage I to III breast cancer who receive MammaPrint® and BluePrint testing on a primary breast tumor are eligible for entry into the FLEX Registry, which is intended to enable additional study arms at low incremental effort and cost. FLEX Registry will utilize an adaptive design, where additional targeted substudies and arms can be added after the initial study is opened.
Principle Investigator:  Cynthia Ma, MD, PhD – Medical Oncologist, Siteman Cancer Center / Professor of Medicine, Division of Oncology, Section of Breast Oncology, Washington University School of Medicine in St. Louis
Sponsor: Agendia
Collaborator: Agendia
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes/Does NOT accept healthy volunteers)
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Cancer Type:  CGCI-Gene and Cellular Immunotherapy

$15 Million Grant Supports WashU Research for Personalized Leukemia Therapies

Trial:  201610088
Disease Site:  Myeloid and Monocytic Leukemia
A Phase II Study of Cytokine Induced Memory-like NK Cell Adoptive Therapy after Haploidentical Donor Hematopoietic Cell Transplantation.   This is a standard phase 2 study powered to demonstrate improvement in the 100 day leukemia free survival to 30% from <10% expected with the use of reduced intensity haplo-HCT in this extremely high-risk patient cohort (based on the institutional experience using non-myeloablative / reduced intensity conditioning in a similar patient cohort).  
Principle Investigator:  Amada Cashen, MD – Bone Marrow Transplant Specialist, Medical Oncologist, Siteman Cancer Center/Washington University School of Medicine in St. Louis
Sponsor: Washington University School of Medicine
Collaborators:  National Institutes of Health (NIH), The V Foundation for Cancer Research, National Cancer Institute (NCI,  ImmunityBio, Inc.
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does not accept healthy volunteers
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  201709041
Disease Site:  Myeloid and Monocytic Leukemia
Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML after Allogeneic Hematopoietic Cell Transplant in Children and Adults.  Phase I/II
Principle Investigator:  Amada Cashen, MD – Bone Marrow Transplant Specialist, Medical Oncologist  Siteman Cancer Center/Washington University School of Medicine in St. Louis
Sponsor: Washington University School of Medicine
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Ages Available for Study: 1 Year and Older (Child/Adult/Older Adult/All Sexes) Does NOT accept healthy volunteers
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  202111115
Disease Site:  Lymphoid Leukemia; Non-Hodgkin Lymphoma
A phase I/II Dose-Escalation and Dose-Expansion Study of the Safety and Efficacy of Anti-CD7 Allogeneic CAR-T Cells (WU-CART -007) in Patients with Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/ Lymphoblastic Lymphoma (LBL). This is a first-in-human, multicenter, Phase I/II, single-agent study in patients with R/R T-ALL/T-LBL who have exhausted other treatment options.
Principle Investigator:  Armini Ghobadi, MD – Bone Marrow Transplant Specialist, Medical Oncologist, Siteman Cancer Center/Washington University School of Medicine in St. Louis
Sponsor: Wugen, Inc.
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Ages Available for Study: 12 Years and Older (Child/Adult/Older Adult/All Sexes) Does not accept healthy volunteers
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  201505024
Disease Site:  Lymphoid Leukemia; Non-Hodgkin Lymphoma
An Open-Label, Multicenter, Phase I/II trial Evaluating the Safety and Pharmacokinetics of Escalating Doses of BTCT4465A as a Single Agent and Combined with Atezolizumab in patients with Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia
Principle Investigator:  Nancy Bartlett, MD – Medical Oncologist (Expertise: Hematologic malignancies/lymphoma) Siteman Cancer Center/Washington University School of Medicine in St. Louis
Sponsor: Genentech, Inc
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Ages Available for Study: (18 Years and Older/Adult/Older Adult/All Sexes) Does not accept healthy volunteers
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  201612068
Disease Site: Hodgkin Lymphoma; Leukemia, other; Lymphoid Leukemia; Multiple Myeloma; Myeloid and Monocytic Leukemia; Non-Hodgkin Lymphoma; Other Hematopoietic
Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study)
Principle Investigator:  Armin Ghobadi, MD – Medical Oncologist, Clinical Expertise:  Leukemia, lymphoma and bone marrow transplant, Siteman Cancer Center / Associate Professor of Medicine, Division of Medical OncologyWashington University School of Medicine in St. Louis
Sponsor: Atara Biotherapeutics
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Ages Available for Study: (Child/Adult/Older Adult/All Sexes) Does not accept healthy volunteers
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  201807049
Disease Site: Lung
A Phase 1 Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 757 in Subjects with Small Cell Lung Cancer
Principle Investigator:  Ramaswamy Govindan – Medical Oncologist, Siteman Cancer Center/Professor of Medicine, Division of Oncology, Washington University School of Medicine in St. Louis
Sponsor: Amgen 
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does not accept healthy volunteers
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  201904212
Disease Site: Soft Tissue
Spearhead 1 Study in Subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma 
A Phase 2 Single Arm Open-Label Clinical Trial of ADP-A2M4 SPEAR T cells in subjects with Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma (SPEARHEAD 1 STUDY)
Principle Investigator:  Brian Van Tine, MD, PhD – Medical Oncologist/Sarcoma Clinical Expertise, Siteman Cancer Center / Professor of Medicine, Oncology, Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor: Adaptimmune 
For Trial Info (800) 600-3606 / Email info@ccadmin.wustl.edu
Ages Available for Study: 10-75 Years (Child/Adult/Older Adult/All Sexes) Does not accept healthy volunteers
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  201907126
Disease Site: Soft Tissue
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered NY-ESO-1-Specific (c259) T Cells, alone or in combination with other agents, in HLA-A2+ Participants with NY-ESO-1 and/or LAGE-1a Positive Solid Tumors
Principle Investigator:  Brian Van Tine, MD, PhD – Medical Oncologist/Sarcoma Clinical Expertise, Siteman Cancer Center / Professor of Medicine, Oncology, Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor: GlaxoSmithKline
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Ages Available for Study: 10 Years and Older (Child/Adult/Older Adult/All Sexes) Does not accept healthy volunteers
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial:  201909144
Disease Site:  Esophagus; Larynx; Lip, Oral Cavity and Pharynx; Lung; Melanoma, Skin; Other Female Genital; Stomach; Urinary Bladder
A Phase 1 Dose Escalation Study to Assess Safety and Efficacy of ADP-A2M4CD8 In HLA-A2+ Subjects With MAGE-A4 Positive Tumors
Principle Investigator:  Brian Van Tine, MD, PhD – Medical Oncologist/Sarcoma Clinical Expertise, Siteman Cancer Center / Professor of Medicine, Oncology, Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor: Adaptimmune
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Ages Available for Study: 18-75 Years (Adult/Older Adult/All Sexes) Does not accept healthy volunteers
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  201912015
Disease Site:  Other Female Genital; Other Respiratory and Intrathoracic Organs; Ovary; Pancreas; Soft Tissue
Study of HPN536 in Patients with Advance Cancers Associated with Mesothelin Expression
A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients with Advanced Cancers Associated with Mesothelin / Expression Who Have Failed Standard Available Therapy
Principle Investigator:  Jeffrey Ward, MD/PhD – Medical Oncologist/Lung Cancer Clinical Expertise / Assistant Professor of Medicine, Division of Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor: Harpoon Therapeutics
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does not accept healthy volunteers
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  202001014
Disease Site:  Lymphoid Leukemia; Non-Hodgkin Lymphoma
FT596 as a Monotherapy and in Combination with Anti-CD20 Monoclonal Antibodies
Principle Investigator:  Armin Ghobadi, MD – Medical Oncologist, Clinical Expertise:  Leukemia, lymphoma and bone marrow transplant, Siteman Cancer Center / Associate Professor of Medicine, Division of Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor: Fate Therapeutics
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does not accept healthy volunteers
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  202001061
Disease Site:  Multiple Myeloma
A Phase 3 Randomized Study Comparing JNJ-68284528, a Chimeric Antigen Receptor 
Tcell (CAR-T) Therapy Directed Against BCMA, versus Pomalidomide, Bortezomib and
Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in
Subjects with Relapsed and Lenalidomide-Refractory Multiple Myeloma (CARTITUDE-4)
Principle Investigator:  Ravi Vig, MD, MBA – Bone Marrow Transplant Specialist / Oncologist, Siteman Cancer Center/Professor of Medicine/Division of Oncology/Section of Bone Marrow Transplantation, Washington University School of Medicine in St. Louis
Sponsor: Janssen Research & Development, LLC
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does not accept healthy volunteers
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial:  202001157
Disease Site:  Non-Hodgkins Lymphoma
A multicenter, open-label, Phase 1 Study to evaluate the safety efficacy, tolerability and pharmacokinetics of escalating doses of R0782859 as a Single Agent and in combination with Obinutuzumb administered after a fixed, single dose pre-treatment of Obinutuzumab (Gazyva/Gayvaro) in patients with relapsed/refractory B-Cell Non-Hodgkins Lymphoma
Principle Investigator:  Nancy Barlett, MD – Medical Oncologist, Siteman Cancer Center / Koman Chair in Medical Oncology, Washington University School of Medicine in St. Louis / Clinical Expertise: Hematologic Malignancies, lymphoma  
Sponsor: Hoffmann-La Roche
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does not accept healthy volunteers
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  202003170
Disease Site:  Lung; Soft Tissue
Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, alone or in combination with other agents, in Participants with Positive Advanced Tumors
Principle Investigator:  Nancy Bartlett, MD – Medical Oncologist (Expertise: Hematologic malignancies/lymphoma) Siteman Cancer Center/Washington University School of Medicine in St. Louis
Sponsor: GlaxcoSmithKline
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does not accept healthy volunteers
Learn more about this study and qualifying criteria at clinicaltrials.gov

Trial:  202004253
Disease Site:  Lymphoid Leukemia
An open-label, multi-centre, Phase Ib/II study evaluating the safety and efficacy of AUTO1, a CAR T Cell Treatment targeting CD19, in Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia.
Principle Investigator:  Armin Ghobadi, MD – Medical Oncologist, Clinical Expertise:  Leukemia, lymphoma and bone marrow transplant, Siteman Cancer Center / Associate Professor of Medicine, Division of Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor:  Autolus Limited
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does not accept healthy volunteers
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial:  202007146
Disease Site:  Hodgkin Lymphona, Leukemia, other Lymphoid Leukemia, Multiple Myeloma; Myeloid and Monocytic Leukemia; Non-Hodgkin Lymphoma; Other Hematopoietic
An open-label, Single-arm, Multicohort, Phase 2 (Cancer Control) Study to assess the Efficacy and Safety of Tabelecleucel in Subjects with Epstein-Barr Virus-associate Diseases
Principle Investigator:  Armin Ghobadi, MD – Medical Oncologist, Clinical Expertise:  Leukemia, lymphoma and bone marrow transplant, Siteman Cancer Center / Associate Professor of Medicine, Division of Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor:  Atara Biotherapeutics
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Ages Available for Study: Child/Adult/Older Adult (All Sexes) Does not accept healthy volunteers
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  202009151
Disease Site:  Lymphoid Leukemia; Non-Hodgkin Lymphoma
A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD19 Allogeneic CRISPR-Cas9Engineered T Cells (CTX110) In Subjects with Relapsed or Refractory B-Cell Malignancies 
Principle Investigator:  Armin Ghobadi, MD – Medical Oncologist, Clinical Expertise:  Leukemia, lymphoma and bone marrow transplant, Siteman Cancer Center / Associate Professor of Medicine, Division of Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor:  CRISPR Therapeutics AG
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does not accept healthy volunteers
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  202012001
Disease Site:  Acute Myeloid Leukemia (AML); Multiple Myeloma; Myeloid and Monocytic Leukemia
A Phase 1, Open-Label, Multicenter Study of FT538 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination with Monoclonal Antibodies in Relapsed/Refractory Multiple Myeloma
Principle Investigator:  Ravi Vig, MD, MBA – Bone Marrow Transplant Specialist / Oncologist, Siteman Cancer Center/Professor of Medicine/Division of Oncology/Section of Bone Marrow Transplantation, Washington University School of Medicine in St. Louis
Sponsor:  Fate Therapeutics
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does not accept healthy volunteers
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  2020102176
Disease Site:  Myeloid and Monocytic Leukemia
A Phase 1 Open-label, Multicenter Study Evaluating the Safety of KITE-222, an Autologous Anti-CLL-1 CAR T-cell Therapy in Subjects with Relapsed/Refractor Acute Myeloid Leukemia
Principle Investigator:  Armin Ghobadi, MD – Medical Oncologist, Clinical Expertise:  Leukemia, lymphoma and bone marrow transplant, Siteman Cancer Center / Associate Professor of Medicine, Division of Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor:  Gilead Sciences
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does not accept healthy volunteers
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  2020103238
Disease Site:  Non-Hodgkin Lymphoma
A phase 1b Study Evaluating the Safety, Tolerability and Preliminary Anti-tumor Activity of NT-17 (efineptakin alfa) a Long acting Human IL-7, post-Tisagenlecleuel (Kymriahâ) in Subjects with Relapsed/Refractory Large B-cell Lymphoma
Principle Investigator:  Armin Ghobadi, MD – Medical Oncologist, Clinical Expertise:  Leukemia, lymphoma and bone marrow transplant, Siteman Cancer Center / Associate Professor of Medicine, Division of Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor:  NeolmmuneTech
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does not accept healthy volunteers
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  2020108127
Disease Site:  Esophagus; Stomach
A Phase 2 Open-Label clinical trial of ADP-A2MACD8 in subjects with advanced esophageal or esophagogastric, junction cancers (surpass-2 study)
Principle Investigator:  Ravi Vig, MD, MBA – Bone Marrow Transplant Specialist / Oncologist, Siteman Cancer Center/Professor of Medicine/Division of Oncology/Section of Bone Marrow Transplantation, Washington University School of Medicine in St. Louis
Sponsor:  Adaptimmune
Collaborator:  ICON pic
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does not accept healthy volunteers
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial:  202201161
Disease Site:  Breast, Larynx; Lip, Oral Cavity and Pharynx; Lung; Stomach; Urinary Bladder
A Phase I (Cancer control), Open-Label, Multicenter Study of FT538 in Combination with Monoclonal Antibodies in Subjects with Advanced Solid Tumors
Principle Investigator:  Haeseong Park, MD, MPH – Oncologist, Center for Advanced Medicine, Siteman Cancer Center Assistant Professor, Medicine Division of Oncology/Washington University School of Medicine in St. Louis
Sponsor:  Fate Therapeutics
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial:  202111018
Disease Site:  Hodgkin Lymphoma; Leukemia, other; Lymphoid Leukemia; Myeloid and Monocytic Leukemia; Non-Hodgkin Lymphoma; Other Hematopoietic
Phase I Dose Escalation and Dose Expansion Study of Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy
Principle Investigator:  Armin Ghobadi, MD – Medical Oncologist, Clinical Expertise:  Leukemia, lymphoma and bone marrow transplant, Siteman Cancer Center / Associate Professor of Medicine, Division of Medical Oncology, Washington University School of Medicine In St. Louis
Sponsor: Washington University School of Medicine
Collaborator:  SecuraBio 
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial:  201510089
Disease Site:  Esophagus; Larynx; Lip, Oral Cavity and Pharynx; Lung; Melanoma, Skin; Other Digestive Organ; Ovary; Soft Tissue; Stomach; Urinary Bladder
A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Solid or Hematological Malignancies
Principle Investigator:  Ramaswamy Govindan – Medical Oncologist, Siteman Cancer Center/Professor of Medicine, Division of Oncology, Washington University School of Medicine in St. Louis
Sponsor: Adaptimmune
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial:  201909180
Disease Site:  Lymphoid Leukemia; Multiple Myeloma; Non-Hodgkin Lymphoma
A Phase 2, Single-Arm, Open-Label Study of Itacitinib, for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy
Principle Investigator:  John F. Dipersio, MD, PhD., Washington University School of Medicine – Virginia E. and Sam J. Goldman Professor in Medicine Chief, Division of Oncology Director, Center for Gene and Cellular Immunotherapy Deputy Director, Alvin J. Siteman Cancer Center/Professor -Department of Medicine Oncology Division: Bone Marrow Transplant & Leukemia Stem Cell Biology, Department of Pediatrics, Department of Pathology & Immunology
Sponsor: Incyte Corporation
Ages Available for Study: 12 Years and Older (Child/Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial:  202009118
Disease Site: 
Serum neurofilament light (NfL) as a marker for brain injury in individuals undergoing chimeric antigen receptor-modified T therapy
Effector Cell Therapy
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu

Cancer Type:  DT/Phase 1

Trial:  201407100
Disease Site: Breast
A Phase 1B Clinical Trial to evaluate the safety and immune response to a Mammaglobin-A DNA Vaccine in ER+, HER2-Breast Cancer in patients undergoing Neoadjuvant Endocrine Therapy or Chemotherapy
Principle Investigator:  William Gillanders, MD Surgical Oncologist, Siteman Cancer Center/Professor / Vice Chair for Research/ Department of Surgery, Washington University School of Medicine in St. Louis
Sponsor: Washington University School of Medicine
Collaborators:  Rising Tide Foundation, United States Department of Defense
Ages Available for Study: 18 Years and Older (Child/Adult/Older Adult/Female) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  201508140

Disease Site: Anus; Bones and Joints; Brain and Nervous System; Breast; Cervix; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Hodgkin Lymphoma; Ill-Defined Sites; Kaposi’s Sarcoma; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, Skin; Mycosis Fungoides; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Unknown Sites; Urinary Bladder
Nivolumab and Ipilimumab in Treating Patients with HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors that are Metastatic or Cannot Be Removed by Surgery
Principle Investigator:  Lee Ratner, MD, Ph.D, Medical Oncologist, Washington University Physicians / Center for Advanced Medicine Siteman Cancer Center/BJC (Sees patients for HIV, AIDS, human immunodeficiency virus, hematology, oncology, AIDS’s related malignancies) Washington University School of Medicine in St. Louis
Sponsor: National Cancer Institute (NCI)
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  201510016
Cancer Type:  Kaposi’s Sarcoma
sEphB4-HAS in Treating Patients with Kaposi Sarcoma
Principle Investigator:  Lee Ratner, MD, Ph.D, Medical Oncologist, Washington University Physicians / Center for Advanced Medicine Siteman Cancer Center/BJC (Sees patients for HIV, AIDS, human immunodeficiency virus, hematology, oncology, AIDS’s related malignancies) Washington University School of Medicine in St. Louis
Sponsor: AIDS Malignancy Consortium
Collaborators:  National Cancer Institute (NCI), Vasgene Therepeutics, Inc, The Emmes Company, LLC, University of Arkansas
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial:  201703028
Disease Site:  Anus; Breast; Colon; Esophagus; Eye and Orbit; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, Skin; Other Digestive Organ; Other Urinary; Pancreas; Prostate; Rectum; Small Intestine; Stomach; Thyroid; Urinary Bladder
Dual Anti-CTLA-4 andAnti-PD-1 blockade in Rare Tumors (Phase II)
Principle Investigator:  Benjamin Tan, MD – Medical Oncologist / Gastrointestinal Cancer Specialist / Associate Professor of Medicine, Division of Oncology, Section of Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor: National Cancer Institute (NCI)
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial:  201711014
Disease Site: Anus; Bones and Joints; Breast; Cervix; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Ill-Defined Sites; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, Skin; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Unknown Sites; Urinary Bladder
A Phase I, Multicenter Dose-escalation and Expansion Study of ARX788 as Monotherapy in Advanced Solid Tumors with HER2-expression or Mutation (ACE-Pan Tumor 01)
Principle Investigator:  Brian Van Tine, MD, PhD – Medical Oncologist/Sarcoma Clinical Expertise, Siteman Cancer Center / Professor of Medicine, Oncology, Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor: National Cancer Institute (NCI)
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  201807070
Disease Site:  Anus; Bones and Joints; Brain and Nervous System; Breast; Cervix; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Ill-Defined Sites; Kaposi’s Sarcoma; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, Skin; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Unknown Sites; Urinary Bladder
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100)
Principle Investigator:  Ramaswamy Govindan – Medical Oncologist, Siteman Cancer Center/Professor of Medicine, Division of Oncology, Washington University School of Medicine in St. Louis
Sponsor: Amgen
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial:  201904006
Disease Site:  Breast; Cervix; Colon; Corpus Uteri; Esophagus; Larynx; Lip, Oral Cavity and Pharynx; Lung; Other Digestive Organ; Other Skin; Ovary; Pancreas; Rectum; Stomach; Urinary Bladder
Principle Investigator:  Haeseong Park, MD, MPH – Oncologist, Center for Advanced Medicine, Siteman Cancer Center Assistant Professor, Medicine Division of Oncology/Washington University School of Medicine in St. Louis
Sponsor:  PsiOxus Therapeutics Ltd
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial: 201904008
Disease Site:  Anus; Bones and Joints; Brain and Nervous System; Breast; Cervix; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Ill-Defined Sites; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, Skin; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Unknown Sites; Urinary Bladder
A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-471 in Patients with Inadequate Responses to PD-1/PD-L1 Checkpoint Inhibitors in Metastatic or Locally Advanced Malignancies (Cancer Control) 
Principle Investigator:  Tanner Johanns, MD, PhD – Medical Oncology/Cancer/Immunotherapy,Primary Brain Tumors, Brain Metastases, Melanoma, Merkel Cell Carcinoma,  Siteman Cancer Center / Washington University School of Medicine in St. Louis / Barnes-Jewish Hospital
Sponsor:  Compass Therapeutics
Collaborator:  Iqvia Pty LTD
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial: 201905001
Disease Site:  Corpus Uteri; Ill-Defined Sites; Larynx; Lip, Oral Cavity and Pharynx; Lung; Unknown Sites
A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects with Metastatic Solid Tumors
Principle Investigator:  Saiama Waqar, MBBS, MSCI – Associate Professor, Department of Medicine, Oncology Division/Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor:  Gilead Sciences
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial: 201905195
Disease Site: Breast; Cervix; Colon; Esophagus; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Lung; Melanoma, Skin; Other Digestive Organ; Rectum; Stomach; Urinary Bladder
A Phase I/II First-in-human Study of BMS-986288 Alone and in Combination with Nivolumab in Advanced Malignant Tumors
Principle Investigator:  Daniel Morgensztern, MD – Professor, Professor, Department of Medicine, Oncology Division/Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor:  Bristol-Myers Squibb
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial: 201906081
Disease Site: Brain and Nervous System; Breast; Colon; Ill-Defined Sites; Kidney; Lip, Oral Cavity and Pharynx; Lung; Other Digestive Organ; Rectum; Soft Tissue; Stomach; Thyroid; Urinary Bladder
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Principle Investigator:  Haeseong Park, MD, MPH – Oncologist, Center for Advanced Medicine, Siteman Cancer Center Assistant Professor, Medicine Division of Oncology/Washington University School of Medicine in St. Louis
Sponsor:  Turning Point Therapeutics, Inc.
Collaborator:  Zai Lab (Shanghai) Co., Ltd.
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial: 201907092
Disease Site: Anus; Breast; Colon; Esophagus; Liver; Lung; Other Digestive Organ; Ovary; Pancreas; Rectum; Small Intestine; Soft Tissue; Stomach; Urinary Bladder
A Phase 1 open-label, multicenter dose escalation study of MT-5111 in subjects with previously treated advanced HER2-positive solid tumors
Principle Investigator:  Brian Van Tine, MD, PhD – Medical Oncologist/Sarcoma Clinical Expertise, Siteman Cancer Center / Professor of Medicine, Oncology, Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor: Molecular Templates, Inc.
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial: 201909144
Disease Site:  Esophagus; Larynx; Lip, Oral Cavity and Pharynx; Lung; Melanoma, Skin; Other Female Genital; Stomach; Urinary Bladder
A Phase 1 Dose Escalation Study To Assess Safety And Efficacy Of ADP-A2M4CD8 In HLA-A2+ Subjects With MAGE-A4 Positive Tumors
Principle Investigator:  Brian Van Tine, MD, PhD – Medical Oncologist/Sarcoma Clinical Expertise, Siteman Cancer Center / Professor of Medicine, Oncology, Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor: Adaptimmune
Collaborator:  ICON plc
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial: 201910170
Disease Site:  Anus; Bones and Joints; Brain and Nervous System; Breast; Cervix; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Ill-Defined Sites; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, Skin; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Unknown Sites; Urinary Bladder
Principle Investigator:  Ramaswamy Govindan – Medical Oncologist, Siteman Cancer Center/Professor of Medicine, Division of Oncology, Washington University School of Medicine in St. Louis
Sponsor: Amgen
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial: 201911172
Disease Site:  Anus; Bones and Joints; Brain and Nervous System; Breast; Cervix; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Hodgkin Lymphoma; Ill-Defined Sites; Kaposi’s Sarcoma; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, Skin; Non-Hodgkin Lymphoma; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Unknown Sites; Urinary Bladder
A First-in-Human, Multicenter, Open-Label, Phase 1 Dose-Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB004 in Subjects with Advanced Solid Malignancies including Lymphoma
Principle Investigator:  Andrew A. Davis, MD – Assistant Professor, Department of Medicine, Oncology Division/Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor: Shanghai Junshi Bioscience Co., Ltd
Collaborators:  TopAlliane Biosciences, Inc., CTI Clinical Trial and Consulting Services
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial: 201912015
Disease Site:  Other Female Genital; Other Respiratory and Intrathoracic Organs; Ovary; Pancreas; Soft Tissue
A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients with Advanced Cancers Associated with Mesothelin Expression Who Have Failed Standard Available Therapy
Principle Investigator:  Jeffrey Ward, MD/PhD – Medical Oncologist/Lung Cancer Clinical Expertise / Assistant Professor of Medicine, Division of Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor: Harpoon Therapeutics
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does not accept healthy volunteers
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial: 201912037
Disease Site:  Anus; Bones and Joints; Brain and Nervous System; Breast; Cervix; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Ill-Defined Sites; Kaposi’s Sarcoma; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, Skin; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Unknown Sites; Urinary Bladder
First-in-human (FIH), Open-Label, Phase 1a (Dose Escalation)/Phase 1b (Expansion Cohort) Trial of BJ-001 as a Single Agent and in Combination with an PD-1 or PD-L1 Inhibitor in Patients with Locally Advanced/Metastatic Solid Tumors
Principle Investigator:  Brian Van Tine, MD, PhD – Medical Oncologist/Sarcoma Clinical Expertise, Siteman Cancer Center / Professor of Medicine, Oncology, Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor: BJ Bioscience, Inc.
Collaborators:  Iquvia Pty Ltd, PPD
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial: 201912097
Disease Site:  Anus; Bones and Joints; Brain and Nervous System; Breast; Cervix; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Ill-Defined Sites; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, Skin; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Unknown Sites; Urinary Bladder
A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination with Pembrolizumab for Participants with Advanced Solid Tumors
Principle Investigator:  Douglas Adkins, MD – Medical Oncologist, Washington University School of Medicine in St. Louis
Sponsor: Merck Sharp & Dohme LLC
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial: 202001160
Disease Site:  Anus; Bones and Joints; Brain and Nervous System; Breast; Cervix; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Ill-Defined Sites; Kidney; Larynx; Liver; Lung; Melanoma, Skin; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Unknown Sites; Urinary Bladder
A Phase 1 (Cancer Control), Multicenter, Open-label, Dose-Exploration and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 650 in Subjects with Advanced Solid Tumors
Principle Investigator:  Ramaswamy Govindan – Medical Oncologist, Siteman Cancer Center/Professor of Medicine, Division of Oncology, Washington University School of Medicine in St. Louis
Sponsor: Amgen
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial: 202003170
Disease Site:  Lung, Soft Tissue
Phase 1 Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, alone or in combination with other agents, in Participants with Advanced Tumors
Principle Investigator:  Brian Van Tine, MD, PhD – Medical Oncologist/Sarcoma Clinical Expertise, Siteman Cancer Center / Professor of Medicine, Oncology, Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor: GlaxoSmithKline
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial: 202004020
Disease Site: Anus; Bones and Joints; Brain and Nervous System; Breast; Cervix; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Hodgkin Lymphoma; Ill-Defined Sites; Kaposi’s Sarcoma; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, Skin; Non-Hodgkin Lymphoma; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Unknown Sites; Urinary Bladder
First in Human, Phase I Trial of Anti-CD47 Antibody ZL-1201 in Subjects with Advanced Cancer
Principle Investigator:  Patrick Grierson, MD, PhD – Medical Oncologist/Instructor of Medicine, Division of Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor: Zai Lab (Shanghai) Co., Ltd.
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial: 202004125
Disease Site: Anus;  Bones and Joints; Brain and Nervous System; Breast; Cervix; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Hodgkin Lymphoma; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Lung Cancer – Non-small Cell; Lung Cancer – Small Cell; Melanoma, Skin; Non-Hodgkin Lymphoma; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Sarcoma; Small Intestine; Soft Tissue; Stomach; Thyroid; Urinary Bladder
A First-in-Human, Open-Label, Multiple-Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of IMC-002 in Subjects with Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas
Principle Investigator:  Brian Van Tine, MD, PhD – Medical Oncologist/Sarcoma Clinical Expertise, Siteman Cancer Center / Professor of Medicine, Oncology, Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor: ImmuneOncia Therapeutics Inc.
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial: 202005122
Disease Site: Anus; Bones and Joints; Breast; Cervix; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Ill-Defined Sites; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, Skin; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Unknown Sites; Urinary Bladder
Principle Investigator:  Jeffrey Ward, MD/PhD – Medical Oncologist/Lung Cancer Clinical Expertise / Assistant Professor of Medicine, Division of Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor: Genmab
Collaborator:  BioNTech SE
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does not accept healthy volunteers
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial: 202006130
Disease Site: Colon; Lung; Other Digestive Organ; Pancreas; Rectum
CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (Cancer Control)
Principle Investigator:  Saiama Waqar, MBBS, MSCI – Associate Professor, Department of Medicine, Oncology Division/Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor:  Elevation Oncology
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial: 202006132
Disease Site: Esophagus; Ill-Defined Sites; Larynx; Lip, Oral Cavity and Pharynx; Lung; Lung Cancer – Non-small Cell
Phase I/II, Two-Part, Multicenter First-in-Human Study of DS-7300a in Subjects with Advanced Solid Malignant Tumors (Cancer Control)
Principle Investigator:  Douglas Adkins, MD – Medical Oncologist, Washington University School of Medicine in St. Louis
Sponsor: Daiichi Sankyo Co., Ltd.
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial: 202007192
Disease Site: Anus; Bones and Joints; Brain and Nervous System; Breast; Cervix; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Ill-Defined Sites; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, Skin; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Unknown Sites; Urinary Bladder
A Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of TST001 in Patients with Locally Advanced or Metastatic Solid Tumors
Principle Investigator:  Brian Van Tine, MD, PhD – Medical Oncologist/Sarcoma Clinical Expertise, Siteman Cancer Center / Professor of Medicine, Oncology, Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor: Mabspace Biosciences (Suzhou) Co., Ltd.
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial: 202008066
Disease Site: Colon; Kidney; Melanoma, Skin; Rectum
An Open-label, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MEDI9253, a Recombinant Newcastle Disease Virus Encoding Interleukin-12, in Combination with Durvalumab in Participants with Select Advanced/Metastatic Solid Tumors
Principle Investigator:  Tanner Johanns, MD, PhD – Medical Oncology/Cancer/Immunotherapy,Primary Brain Tumors, Brain Metastases, Melanoma, Merkel Cell Carcinoma,  Siteman Cancer Center / Washington University School of Medicine in St. Louis / Barnes-Jewish Hospital
Sponsor:  AstraZeneca
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial: 202008123
Disease Site: Breast; Cervix; Ill-Defined Sites; Kidney; Lip, Oral Cavity and Pharynx; Lung; Lung Cancer – Non-small Cell; Lung Cancer – Small Cell; Melanoma, Skin; Stomach 
A Phase I First-in-human Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD8701 Administered Intravenously as Monotherapy and in Combination with Durvalumab (MEDI4736) in Participants with Advanced Solid Tumors (Cancer control)
Principle Investigator:  Nusayba Bagegni, MD – Medical Oncologist, Siteman Cancer Center / Assistant Professor of Medicine, Division of Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor: AstraZeneca 
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email:  info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:   clinicaltrials.gov

Trial: 202008198
Disease Site: Kidney; Lip, Oral Cavity and Pharynx; Lung; Lung Cancer – Non-small Cell; Melanoma, Skin; Other Skin
A Phase 1 Study to Evaluate Safety, Tolerability,Pharmacokinetics and Pharmacodynamics of AMG 256 in Patients With Advanced Solid
Tumors
Principle Investigator:  Ramaswamy Govindan – Medical Oncologist, Siteman Cancer Center/Professor of Medicine, Division of Oncology, Washington University School of Medicine in St. Louis
Sponsor: Amgen
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial: 202009092
Disease Site: Anus; Bones and Joints; Brain and Nervous System; Breast; Cervix; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Lung Cancer – Non-small Cell; Melanoma, Skin; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Urinary Bladder
A two-part, Phase 1A/B, Open-Label, Multicenter Trial Evaluating Pharmacokinetics, safety and efficacy of PF-07284890 (ARRY-461) in participants with BRAF V600-Mutant Solid Tumors with and without Brain Involvement
Principle Investigator:  George Ansstas, MD – Medical Oncologist, Neuro-Oncologist / Professor of Medicine, Section of Medical Oncology, Division of Oncology, Washington University School of Medicine in St. Louis
Sponsor: Pfizer
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial: 202010115
Disease Site: Anus; Bones and Joints; Brain and Nervous System; Breast; Cervix; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Kaposi’s Sarcoma; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, Skin; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Urinary Bladder
A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients with Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
Principle Investigator:  Kian-Huat Lim, MD, PhD – Associate Professor, Department of Medicine Oncology Division, Molecular Oncology, Washington University School of Medicine in St. Louis
Sponsor: BioMed Valley Discoveries, Inc
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial: 202102009
Disease Site: Anus; Bones and Joints; Brain and Nervous System; Breast; Cervix; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Kaposi’s Sarcoma; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Lung Cancer – Non-small Cell; Lung Cancer – Small Cell; Melanoma, Skin; Metastatic Disease; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Sarcoma; Small Intestine; Soft Tissue; Stomach; Thyroid; Urinary Bladder
A phase Ib/II open-label, multi-center dose escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation
Principle Investigator:  Ramaswamy Govindan – Medical Oncologist, Siteman Cancer Center/Professor of Medicine, Division of Oncology, Washington University School of Medicine in St. Louis
Sponsor: Novartis Pharmaceuticals
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial: 202103029
Disease Site: Colon; Lung; Pancreas; Rectum
A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-3312 in Combination with Pembrolizumab or Binimetinib in Adult Patients with Advanced Solid Tumors
Principle Investigator:  Daniel Morgensztern, MD – Medical Oncologist/ Profesor of Medicine, Division of Oncology, Section of Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor: Jacobio Pharmaceuticals Co., Ltd.
Collaborator:  AbbVie
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial: 202105015
Disease Site: Breast; Cervix; Colon; Lung; Lung Cancer – Non-small Cell; Rectum; Urinary Bladder
An Open-Label Multicenter Phase Ib Study of AN0025 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors
Principle Investigator:  Katherine Clifton, MD – Medical Oncologist / Assistant Professor of Medicine, Division of Oncology, Section of Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor: Adlai Nortye Biopharma Co., Ltd.
Collaborator:  Merck Sharp & Dohme LLC
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial: 202105139
Disease Site: Anus; Breast; Colon; Esophagus; Larynx; Lip, Oral Cavity and Pharynx; Lung; Lung Cancer – Non-small Cell; Metastatic Disease; Pancreas; Rectum
A Phase 1, First-in-human Study of the Safety, Single- and Multiple-Dose Pharmacokinetics, and Preliminary Activity of Escalating Doses of RBN-2397, an Oral PARP7 Inhibitor, in Patients with Solid Tumors
Principle Investigator:  Saiama Waqar, MBBS, MSCI – Associate Professor, Department of Medicine, Oncology Division/Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor:  Ribon Therapeutics, Inc.
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial: 202105147
Disease Site: Esophagus; Stomach
Phase 1/1b Trial of ATR Inhibitor BAY 1895344 in Combination with FOLFIRI in GI Malignancies with a Focus on Metastatic Colorectal and Gastric/Gastroesophageal Cancers
Principle Investigator:  Patrick Grierson, MD, PhD – Medical Oncologist/Instructor of Medicine, Division of Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor: National Cancer Institute (NCI)
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial: 202105166
Disease Site: Breast; Cervix; Corpus Uteri; Esophagus; Larynx; Lip, Oral Cavity and Pharynx; Lung; Lung Cancer – Non-small Cell; Other Female Genital; Ovary; Pancreas; Prostate
A Phase 1 Dose Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors (Cancer Control)
Principle Investigator:  Mia C. Weiss, MD – Medical Oncologist / Assistant Professor of Medicine, Division of Oncology, Washington University School of Medicine in St. Louis
Sponsor:  Exelixis
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial: 202111197
Disease Site: Anus; Breast; Cervix; Colon; Corpus Uteri; Esophagus; Liver; Other Digestive Organ; Other Female Genital; Ovary; Pancreas; Rectum; Small Intestine; Stomach
A Phase I/IIa Multi-center, Open-label Master Protocol to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of AZD8205 in Participants with Advanced or Metastatic Solid Malignancies
Principle Investigator:  Andrew A. Davis, MD – Assistant Professor, Department of Medicine, Oncology Division/Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor: AstraZeneca
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial: 202112140
Disease Site: Anus; Breast; Colon; Kidney; Lip, Oral Cavity and Pharynx; Liver; Lung; Other Digestive Organ; Other Respiratory and Intrathoracic Organs; Other Urinary; Pancreas; Rectum; Small Intestine; Stomach; Urinary Bladder
A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination with Docetaxel in Subjects with Advanced MTAP-null Solid Tumors (Cancer Control)
Principle Investigator:  Siddhartha Devarakonda, MBBS, MD – Assistant Professor, Department of Medicine Oncology Division/Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor: Amgen
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial: 202201030
Disease Site:  Breast; Colon; Esophagus; Lung; Pancreas; Rectum; Stomach
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGC936-0901 (Anti-ADAM9 Antibody Drug Conjugate) in Patients with Advanced Solid Tumors
Principle Investigator:  Andrew A. Davis, MD – Assistant Professor, Department of Medicine, Oncology Division/Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor:  ImmunoGen, Inc.
Collaborator:  MacroGenics
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial: 202201124
Disease Site:  Anus; Breast; Cervix; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Lung; Melanoma, Skin; Stomach; Urinary Bladder
A Phase 1b, Open-label, Dose-escalation Trial Of The Safety Of And Antigen-specific Immune Responses Elicited By Vb.10 Neo In Combination With Atezolizumab In Subjects With Locally Advanced And Metastatic Tumors
Principle Investigator:  Nikolaos Trikalinos, MD – Medical Oncologist, Siteman Cancer Center / Assistant Professor, Medicine Division of Oncology, Washington University School of Medicine
Sponsor:  Nykode Therapeutics AS
Collaborator:  Genentech, Inc.
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Cancer Type:  Gastrointestinal

St. Louis-Based Geneoscopy is Having Success with At-Home Colorectal Cancer Screening Tests

Trial: 201709013
Disease Site:  Liver
An early Phase 1 Multicenter Pilot Study of Nivolumab with Drug Eluting Bead Transarterial Chemoembolization in Patients with Advanced Hepatocellular Carcinoma
Principle Investigator:  Benjamin Tan, MD – Medical Oncologist / Gastrointestinal Cancer Specialist / Associate Professor of Medicine, Division of Oncology, Section of Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor: Memorial Sloan Kettering Cancer Center
Collaborator:  Bristol-Myers Squibb
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial: 201902040
Disease Site:  Rectum
Phase I study of epacadostat (INCB024360) added to preoperative chemoradiation in patients with locally advanced rectal cancer
Principle Investigator:  Katrina Pederson, MD, MS – Medical Oncologist /Assistant Professor of Medicine, Division of Medical Oncology, Washington University School of Medicine in St. Louis 
Sponsor: Washington University School of Medicine 
Collaborator:  Incyte Corporation
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial: 201904029
Disease Site:  Rectum
Phase II Non-Operative Management and Early Response Assessment in Rectal Cancer (NOM-ERA)
Principle Investigator:  Hyun Kim, MD – Chief, Gastrointestinal Services, Chief, MR-Guided Radiotherapy / Assistant Professor of Radiation Oncology
Sponsor: Washington University School of Medicine 
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial: 201909019

Disease Site:  Esophagus, Stomach
Phase I Study of Radiation Dose Intensification with Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer
Principle Investigator:  Shahed N. Badiyan, MD – Radiation Oncologist/ Associate Professor of Radiation Oncology, Washington University School of Medicine
Sponsor: Washington University School of Medicine 
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial: 201911059
Disease Site:  Stomach
MR-guided Pre-operative RT in Gastric Cancer
Principle Investigator:  Hyun Kim, MD – Chief, Gastrointestinal Services, Chief, MR-Guided Radiotherapy / Assistant Professor of Radiation Oncology
Sponsor: Washington University School of Medicine
Collaborator:  Viewray Inc.  
Ages Available for Study: 19 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial: 202007173
Disease Site:  Brain and Nervous System; Colon; Lung; Other Digestive Organ; Other Endocrine System; Other Respiratory and Intrathoracic Organs; Other Skin; Pancreas; Prostate; Rectum; Small Intestine; Stomach; Unknown Sites
Phase II Cabozantinib in high grade neuroendocrine neoplasms
Principle Investigator:  Nikolaos Trikalinos, MD – Medical Oncologist, Siteman Cancer Center / Assistant Professor, Medicine Division of Oncology, Washington University School of Medicine
Sponsor: Washington University School of Medicine
Collaborator:  Exelixis
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial: 202011125
Testing the immunologic effects of CDX-301 and CDX-1140 in resectable pancreatic cancer patients
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu

Trial: 202103218
Disease Site:  Anus; Colon; Rectum
Hypofractionated Pencil-Beam Scanning Intensity-modulated Proton Therapy (IMPT) in the Reirradiation of Locoregionally Recurrent Rectal Cancer – IMPARC
Principle Investigator:  Shahed N. Badiyan, MD – Radiation Oncologist/ Associate Professor of Radiation Oncology, Washington University School of Medicine
Sponsor: Washington University School of Medicine 
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:   clinicaltrials.gov

Trial: 202106061
Disease Site:  Pancreas
Phase II Study of Stereotactic Body Radiotherapy and Focal Adhesion Kinase Inhibitor in Advanced Pancreas Adenocarcinoma
Principle Investigator:  Hyun Kim, MD – Chief, Gastrointestinal Services, Chief, MR-Guided Radiotherapy / Assistant Professor of Radiation Oncology
Sponsor: Washington University School of Medicine
Collaborators:  National Cancer Institute (NCI), Verastem, Inc.  
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial: 2021710206
Disease Site:  Colon
Phase III Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy for Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair
Principle Investigator:  Katrina Pederson, MD, MS – Medical Oncologist /Assistant Professor of Medicine, Division of Medical Oncology, Washington University School of Medicine in St. Louis 
Sponsor: National Cancer Institute (NCI) 
Collaborator:  Incyte Corporation
Ages Available for Study: 12 Years and Older (Child/Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial:  201807070
Disease Site:  Anus; Bones and Joints; Brain and Nervous System; Breast; Cervix; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Ill-Defined Sites; Kaposi’s Sarcoma; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, Skin; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Unknown Sites; Urinary Bladder
A Phase 1/11, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects with Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C Mutation (CodeBreak 100)
Principle Investigator:  Ramaswamy Govindan, MD – Medical Oncologist, Siteman Cancer Center/Professor of Medicine, Division of Oncology, Washington University School of Medicine in St. Louis
Sponsor: Amgen
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial:  201808122
Disease Site:  Anus; Colon; Esophagus; Liver; Lung; Other Digestive Organ; Pancreas; Rectum; Small Intestine; Stomach; Unknown Sites
Phase III Randomized, Double-blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumors after Progression on Everolimus
Principle Investigator:  Nikolaos Trikalinos, MD – Medical Oncologist, Siteman Cancer Center / Assistant Professor, Medicine Division of Oncology, Washington University School of Medicine
Sponsor: National Cancer Institute (NCI)
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial:  201808178
Disease Site:  Esophagus; Stomach
A Phase II (Cancer Control) study of chemotherapy and immune checkpoint blockade with Pembrolizumab in the perioperative and maintenance treatment of locoregional gastric or GE junction adenocarcinoma.
Principle Investigator:  Kian-Huat Lim, MD, PhD – Associate Professor, Department of Medicine Oncology Division, Molecular Oncology, Washington University School of Medicine in St. Louis
Sponsor: Gulam Manji
Collaborator:  Merck Sharp & Dohme LLC
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.eduLearn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial:  201910170
Disease Site:  Anus; Bones and Joints; Brain and Nervous System; Breast; Cervix; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Ill-Defined Sites; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, Skin; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Unknown Sites; Urinary Bladder
A Phase 1b/2, Master Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 510 (pINN Sotorasib) in Subjects with Advanced Solid Tumors with KRAS p.G12C Mutation
Principle Investigator:  Ramaswamy Govindan, MD – Medical Oncologist, Siteman Cancer Center/Professor of Medicine, Division of Oncology, Washington University School of Medicine in St. Louis
Sponsor: Amgen
Ages Available for Study: 18 -100 Years (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial: 201911054
Disease Site:  Other Digestive Organ
Phase II Study of Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan in Previously Treated Advanced Biliary Tract Cancer (NAPOLI-2)
Principle Investigator:  Katrina Pederson, MD, MS – Medical Oncologist /Assistant Professor of Medicine, Division of Medical Oncology, Washington University School of Medicine in St. Louis 
Sponsor: Georgetown University
Collaborator:  Ipsen
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial: 201911155
Disease Site:  Pancreas
A Phase 1(Cancer Control) Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants with Gastrointestinal Malignancies
Principle Investigator:  Kian-Huat Lim, MD, PhD – Associate Professor, Department of Medicine Oncology Division, Molecular Oncology, Washington University School of Medicine in St. Louis
Sponsor: Arcus Biosciences, Inc.
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial: 201911159
Disease Site:  Pancreas
A Phase III (Cancer Control) Precision Promise Platform Trial for Metastatic Pancreatic Cancer 
Principle Investigator:  Kian-Huat Lim, MD, PhD – Associate Professor, Department of Medicine Oncology Division, Molecular Oncology, Washington University School of Medicine in St. Louis
Sponsor: Pancreatic Cancer Action Network
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial: 201912015
Disease Site:  Other Female Genital; Other Respiratory and Intrathoracic Organs; Ovary; Pancreas; Soft Tissue
A Phase 1/2a Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN536 in Patients with Advanced Cancers Associated with Mesothelin Expression Who Have Failed Standard Available Therapy
Principle Investigator:  Jeffrey Ward, MD/PhD – Medical Oncologist/Lung Cancer Clinical Expertise / Assistant Professor of Medicine, Division of Medical Oncology, Washington University School of Medicine in St. Louis
Sponsor: Harpoon Therapeutics
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does not accept healthy volunteers
Learn more about this study and qualifying criteria at: clinicaltrials.gov

Trial: 201912097
Disease Site:  Anus; Bones and Joints; Brain and Nervous System; Breast; Cervix; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Ill-Defined Sites; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Melanoma, Skin; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Unknown Sites; Urinary Bladder
A Phase 1 Open Label, Multi-Arm, Multicenter Study of MK-4830 as Monotherapy and in Combination with Pembrolizumab for Participants with Advanced Solid Tumors
Principle Investigator:  Douglas Adkins, MD – Medical Oncologist, Washington University School of Medicine in St. Louis
Sponsor: Merck Sharp & Dohme LLC
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial: 201912123
Disease Site:  Colon; Rectum
Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in patients with previously untreated Metastatic Colorectal Cancer (Solaris)
Principle Investigator:  Katrina Pederson, MD, MS – Medical Oncologist /Assistant Professor of Medicine, Division of Medical Oncology, Washington University School of Medicine in St. Louis 
Sponsor: Alliance for Clinical Trials in Oncology
Collaborator:  National Cancer Institute (NCI)
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:  clinicaltrials.gov

Trial:  202001128
Disease Site:  Colon; Esophagus; Liver; Other Digestive Organ; Pancreas; Rectum; Stomach
A phase I/Ib, open-label, multi-center, study of KAZ954 as a single agent and in combination with Spartalizumab, NZV930 and NIR178 in patients with advanced solid tumors
Principle Investigator:  Mia C. Weiss, MD – Medical Oncologist / Assistant Professor of Medicine, Division of Oncology, Washington University School of Medicine in St. Louis
Sponsor:  Novartis Phamaceuticals
Ages Available for Study: 18 Years and Older (Adult/Older Adult/All Sexes) Does Not accept heathy volunteers
For Trial Info: (800) 600-3606 / Email info@ccadmin.wustl.edu
Learn more about this study and qualifying criteria at:   clinicaltrials.gov